David Lebwohl - 21 Sep 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Medical Officer
Signature: /s/James Basta, Attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 21 Sep 2021
Net transactions value: -$329,256
Form type: 4
Filing time: 23 Sep 2021, 17:48:09 UTC
Previous filing: 01 Sep 2021
Next filing: 27 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise	$30,288	+2,400	+303%	$12.62	3,191	21 Sep 2021	Direct
transaction	NTLA	Common Stock	Sale	$359,544	-2,400	-75%	$149.81	791	21 Sep 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Options Exercise	$0	-2,400	-1.2%	$0.000000	192,800	21 Sep 2021	Common Stock	2,400	$12.62	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2	The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,666 shares as of September 21, 2021.